Absci Corporation Common Stock (ABSI)
Absci Corporation is a biotechnology company specializing in artificial intelligence-driven drug discovery and development. It leverages its proprietary platform to streamline the creation of biologics and identify new therapeutic candidates efficiently, aiming to accelerate the journey from discovery to clinical trials.
Company News
Absci Corp, a small AI biotech company, offers high-risk investment potential in drug discovery using generative AI, with multiple drug candidates in clinical trials and strategic partnerships with major pharma companies.
The global CADD market is experiencing rapid growth, projected to generate substantial revenue between 2025-2034, driven by technological innovations, AI integration, and increasing demand across pharmaceutical and research sectors.
Absci partnered with Oracle Cloud Infrastructure and AMD to accelerate AI-driven drug discovery, leveraging high-performance computing infrastructure for molecular simulations and antibody design.
Cathie Wood's Ark Invest has been buying shares of Tempus AI, Blade Air Mobility, and Absci despite a rough year for growth investors. Tempus AI and Absci are using AI for healthcare solutions, while Blade Air Mobility operates a helicopter transport service.
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.